Equities analysts expect DENTSPLY SIRONA Inc (NASDAQ:XRAY) to post $951.79 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for DENTSPLY SIRONA’s earnings, with the highest sales estimate coming in at $1.02 billion and the lowest estimate coming in at $917.80 million. DENTSPLY SIRONA posted sales of $1.01 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 5.8%. The business is expected to report its next quarterly earnings results on Friday, November 2nd.
According to Zacks, analysts expect that DENTSPLY SIRONA will report full-year sales of $3.99 billion for the current year, with estimates ranging from $3.95 billion to $4.13 billion. For the next fiscal year, analysts forecast that the company will report sales of $4.09 billion, with estimates ranging from $3.98 billion to $4.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.01. DENTSPLY SIRONA had a positive return on equity of 9.12% and a negative net margin of 39.62%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the firm earned $0.65 earnings per share.
A number of institutional investors have recently added to or reduced their stakes in XRAY. UBS Group AG boosted its holdings in DENTSPLY SIRONA by 15.4% in the first quarter. UBS Group AG now owns 201,617 shares of the medical instruments supplier’s stock worth $10,143,000 after acquiring an additional 26,951 shares in the last quarter. A.R.T. Advisors LLC boosted its holdings in DENTSPLY SIRONA by 329.7% in the first quarter. A.R.T. Advisors LLC now owns 31,800 shares of the medical instruments supplier’s stock worth $1,599,000 after acquiring an additional 24,400 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in DENTSPLY SIRONA by 3.5% in the first quarter. The Manufacturers Life Insurance Company now owns 328,361 shares of the medical instruments supplier’s stock worth $16,521,000 after acquiring an additional 10,959 shares in the last quarter. Natixis bought a new stake in DENTSPLY SIRONA in the first quarter worth $3,768,000. Finally, LPL Financial LLC boosted its holdings in DENTSPLY SIRONA by 12.3% in the first quarter. LPL Financial LLC now owns 47,484 shares of the medical instruments supplier’s stock worth $2,389,000 after acquiring an additional 5,201 shares in the last quarter. 97.56% of the stock is currently owned by institutional investors and hedge funds.
Shares of XRAY traded up $0.61 during mid-day trading on Wednesday, hitting $36.28. 4,193,512 shares of the company’s stock traded hands, compared to its average volume of 2,566,803. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.69. DENTSPLY SIRONA has a 1 year low of $35.30 and a 1 year high of $68.98. The stock has a market capitalization of $7.93 billion, a PE ratio of 13.64, a price-to-earnings-growth ratio of 2.07 and a beta of 1.20.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
See Also: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.